Share

April 2017; 3 (2) ArticleOpen Access

Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark

Nanna Witting, Ulla Werlauff, Morten Duno, John Vissing
First published March 21, 2017, DOI: https://doi.org/10.1212/NXG.0000000000000140
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1095

Share

Article Information

vol. 3 no. 2 e140
DOI: 
https://doi.org/10.1212/NXG.0000000000000140
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • Received September 16, 2016
  • Accepted in final form January 30, 2017
  • First Published March 21, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Nanna Witting, MD, PhD,
    2. Ulla Werlauff, PT, PhD,
    3. Morten Duno, PhD and
    4. John Vissing, MD, DMSci
  1. Nanna Witting, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. The Danish Council for Independent Research 4004-00438B, Stipendium to do part time research

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Novo Nordisk Foundation. The Jascha foundation The Gangsted foundation The Augustinus foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ulla Werlauff, PT, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Morten Duno, PhD and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. John Vissing, MD, DMSci
    5. Scientific Advisory Boards:

    1. Served on advisory boards for Alexion, Sarepta and Genzyme Corporations

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel and speaker honoraria from Genzyme

    Editorial Boards:

    1. Editorial Board member for Neuromuscualr Disorders, and Journal of Neuromuscular Diseases

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Has been (but not presently) consultant for NOVO Nordic, Lundbeck, Ultragenyx, aTyr Pharma

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Ultragenyx Pharmaceuricals, aTyr Pharma, Genzyme

    Research Support, Government Entities:

    1. Danishh Medical Research Council

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Augustinus Foundation NOVO Nordic Foundation Lundbeck Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Copenhagen Neuromuscular Center (N.W., J.V.), Department of Neurology, and Department of Clinical Genetics (U.W.), Rigshospitalet, University of Copenhagen; and The Danish National Rehabilitation Centre for Neuromuscular Diseases (M.D.), Aarhus, Denmark.
  1. Correspondence to Dr. Witting: nanna.witting{at}regionh.dk
View Full Text

Article usage

Article usage: March 2017 to February 2023

AbstractFullPdfSource
Mar 201711815914Highwire
Apr 201732922155Highwire
May 20171293188Highwire
Jun 2017392411Highwire
Jul 201738811Highwire
Aug 20171766Highwire
Sep 20171609Highwire
Oct 201713411Highwire
Nov 2017546Highwire
Dec 20171326Highwire
Jan 201840259Highwire
Feb 2018371911Highwire
Mar 20184329Highwire
Apr 20180144Highwire
May 2018067Highwire
Jun 20180158Highwire
Jul 201811610Highwire
Aug 20182245Highwire
Sep 201817010Highwire
Oct 20183449Highwire
Nov 201825610Highwire
Dec 20185838Highwire
Jan 20192477Highwire
Feb 201984015Highwire
Mar 201903225Highwire
Apr 201994511Highwire
May 201912111Highwire
Jun 201943519Highwire
Jul 201934523Highwire
Aug 201902810Highwire
Sep 20190839Highwire
Oct 201949815Highwire
Nov 20191199Highwire
Dec 201928813Highwire
Jan 20201759Highwire
Feb 202003317Highwire
Mar 202032516Highwire
Apr 202035030Highwire
May 2020411222Highwire
Jun 20206747Highwire
Jul 202015112Highwire
Aug 20201408Highwire
Sep 2020313617Highwire
Oct 202048011Highwire
Nov 202036520Highwire
Dec 202053419Highwire
Jan 20210257Highwire
Feb 202131511Highwire
Mar 202111621Highwire
Apr 202141317Highwire
May 202123022Highwire
Jun 202111712Highwire
Jul 202121822Highwire
Aug 202123132Highwire
Sep 202112519Highwire
Oct 202133357Highwire
Nov 202112218Highwire
Dec 202101511Highwire
Jan 20221914Highwire
Feb 2022465Highwire
Mar 202222516Highwire
Apr 202211811Highwire
May 202242613Highwire
Jun 202221016Highwire
Jul 20221134Highwire
Aug 202202010Highwire
Sep 202229414Highwire
Oct 202236515Highwire
Nov 2022511916Highwire
Dec 2022122910Highwire
Jan 2023425114Highwire
Feb 2023511816Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles